

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 13178

Title: Incretin-based therapies in prediabetes: current evidence and future perspectives.

Reviewer code: 00608229

Science editor: Yue-Li Tian

Date sent for review: 2014-08-11 08:37

Date reviewed: 2014-08-19 18:00

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input checked="" type="checkbox"/> [Y] Grade A: Excellent	<input checked="" type="checkbox"/> [Y] Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> [Y] Accept
<input type="checkbox"/> [] Grade B: Very good	<input type="checkbox"/> [] Grade B: Minor language polishing	<input type="checkbox"/> [] Existing	<input type="checkbox"/> [] High priority for publication
<input type="checkbox"/> [] Grade C: Good	<input type="checkbox"/> [] Grade C: A great deal of language polishing	<input type="checkbox"/> [] No records	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> [] Grade D: Fair	<input type="checkbox"/> [] Grade D: Rejected	BPG Search:	<input type="checkbox"/> [] Minor revision
<input type="checkbox"/> [] Grade E: Poor		<input type="checkbox"/> [] Existing	<input type="checkbox"/> [] Major revision
		<input type="checkbox"/> [] No records	

COMMENTS TO AUTHORS

Appropriate evaluation of relevant information has been applied, whereas the conclusions are persuasively supported by data presentation and interpretation. Minor concerns and suggestions are provided below. 1. The length of the "Introduction" section and the "Molecular intracellular mechanisms of GLP-1 activity" section should be limited to two thirds of the current version at most. 2. Are there any data on saxagliptin for prediabetes? 3. The "safety" section should be shortened as well, since it almost exclusively refers to subjects with diabetes.

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 13178

Title: Incretin-based therapies in prediabetes: current evidence and future perspectives.

Reviewer code: 00607640

Science editor: Yue-Li Tian

Date sent for review: 2014-08-11 08:37

Date reviewed: 2014-08-20 16:03

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Reviewer's Comments: The author reviewed the incretin-based therapies in prediabetes. This manuscript includes the current evidence of incretin based therapies when administered in a prediabetic state, both in animal models and in humans. This review article could be helpful both in clinic and basic medical study.

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 13178

Title: Incretin-based therapies in prediabetes: current evidence and future perspectives.

Reviewer code: 02615858

Science editor: Yue-Li Tian

Date sent for review: 2014-08-11 08:37

Date reviewed: 2014-08-26 17:13

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This paper reviews the incretin-based therapies in prediabetes, summarizing current evidences of prediabetes treatment with DPP-4 inhibitors and GLP-1R agonists in animal models and in humans. The manuscript is well presented and is of interest, providing useful information on this topic. Minor points: 1. A reference to clinical trials as well as to the use of some other inhibitors (such as saxagliptin, linagliptin, etc) should be included in the "Other DPP-4 inhibitors" section. 2. A reference to cost-effectiveness of incretin-based therapies in prediabetes should be quoted. 3. Numerical data from references should be rechecked, since some differences have been detected. 4. The "Safety of incretin-based therapies" section should be extensively shortened. 5. English language needs some minor polishing and text editing.